Events
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
-
-
AI’s potential in skin cancer management comes with a warning
Artificial intelligence (AI) use in dermatology is primed to become a powerful tool in skin…
Hair dye and cancer risk: Largest study yet
Hair dyes contain certain chemicals that have been held responsible for these relationships. In the…
‘Social smokers’ face disproportionate risk of death from lung disease and lung cancer
‘Social smokers’ are more than twice as likely to die of lung disease and more…
Breast cancer patients could benefit from controversial hormone
An international team of researchers involving the University of Adelaide is tackling the controversy over what some scientists consider to…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.